Although one out of six mice in anti-PD-L1 monotherapy reached CR, four mice in the group receiving combination therapy of anti-TNFR2 with anti-PD-L1 reached CR, and the tumor growth was significantly suppressed (Figure 6A). The gene discussed is TNFRSF1B; the disease is neoplasm.